Особенности антитромботической терапии у пациентов с мультифокальным поражением артерий
Аннотация
Мультифокальное поражение артерий часто встречается у пациентов с атеросклеротическими сердечно-сосудистыми заболеваниями и ассоциируется с повышенным риском развития сердечно-сосудистых осложнений и смерти. Применение более интенсивной антитромботической терапии, особенно комбинации ацетилсалициловой кислоты и «сосудистой» дозы ривароксабана, у пациентов с мультифокальным поражением артерий характеризуется благоприятным соотношением эффективности и безопасности за счет выраженного снижения риска развития сердечно-сосудистых осложнений. Выявление заболеваний периферических артерий у пациентов с ишемической болезнью сердца и атеросклеротической цереброваскулярной патологией дает возможность улучшить стратификацию риска, оптимизировать диагностическую тактику и уточнить показания к более интенсивной антитромботической терапии.
Об авторах
В. Г. Грачев
ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России, Екатеринбург
Россия
Россия
кафедра факультетской терапии, эндокринологии, аллергологии и иммунологии, доцент
С. С. Веденская
ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России, Екатеринбург
Россия
Россия
кафедра факультетской терапии, эндокринологии, аллергологии и иммунологии, доцент
О. Г. Смоленская
ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России, Екатеринбург
Россия
Россия
кафедра факультетской терапии, эндокринологии, аллергологии и иммунологии, профессор, зав. кафедрой
Список литературы
1. Bonaca MP. Polyvascular disease and risk: When two is not better than one. Vascular Medicine. 2018;23(6):531–3. DOI: 10.1177/1358863X18796936
2. Desormais I, Vlachopoulos C, Aboyans V. Panvascular disease - Epidemiology and prevention. Cor et Vasa. 2018;60(1):e3–8. DOI: 10.1016/j.crvasa.2017.12.004
3. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal. 2018;39(9):763–816. DOI: 10.1093/eurheartj/ehx095
4. Акберов Р.Ф., Шарафеев А.З., Михайлов М.К., Зыятдинов К.Ш., Коробов В.В., Абашев А.Р. и др. Прогрессирующий мультифокальный атеросклероз: этиология, клинико-лучевая диагностика, современные аспекты лечения. - Казань: Идел-Пресс; 2008. - 214с. ISBN 978-5-85247-200-7
5. Барбараш О.Л., Кашталап В.В. Выявление латентного некоронарного атеросклероза у пациентов с острым коронарным синдромом. Есть ли смысл? Комплексные проблемы сердечно-сосудистых заболеваний. 2012;1:12-6
6. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL et al. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA. 2006;295(2):180–9. DOI: 10.1001/jama.295.2.180
7. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (London, England). 1996;348(9038):1329–39. DOI: 10.1016/s0140-6736(96)09457-3
8. Steg PhG, Bhatt DL, Wilson PWF, D’Agostino R, Ohman EM,
9. Röther J et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA. 2007;297(11):1197–206. DOI: 10.1001/jama.297.11.1197
10. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM et al. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA. 2010;304(12):1350–7. DOI: 10.1001/jama.2010.1322
11. Hirsh J, Bhatt DL. Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations: Lessons From the CAPRIE and CURE Studies. Archives of Internal Medicine. 2004;164(19):2106–10. DOI: 10.1001/archinte.164.19.2106
12. Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard J-M, Agnelli G et al. Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of EvidenceBased Therapies (from the Global Registry of Acute Coronary Events). The American Journal of Cardiology. 2007;100(1):1–6. DOI: 10.1016/j.amjcard.2007.02.046
13. Bhatt DL, Peterson ED, Harrington RA, Ou F-S, Cannon CP, Gibson CM et al. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. European Heart Journal. 2009;30(10):1195–202. DOI: 10.1093/eurheartj/ehp099
14. Ferreira-González I, Miralda GP, Heras M, Ribera A, Marsal JR, Cascant P et al. Prognosis and Management of Patients With Acute Coronary Syndrome and Polyvascular Disease. Revista Española de Cardiología (English Edition). 2009;62(9):1012–21. DOI: 10.1016/S1885-5857(09)73267-0
15. Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP et al. Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non–ST- Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes. 2012;5(4):541–9. DOI: 10.1161/CIRCOUTCOMES.111.964379
16. Attar R, Wester A, Koul S, Eggert S, Andell P. Peripheral artery disease and outcomes in patients with acute myocardial infarction. Open Heart. 2019;6(1):e001004. DOI: 10.1136/openhrt-2018-001004
17. Heldner MR, Li L, Lovett NG, Kubiak MM, Lyons S, Rothwell PM et al. Long-Term Prognosis of Patients With Transient Ischemic Attack or Stroke and Symptomatic Vascular Disease in Multiple Arterial Beds. Stroke. 2018;49(7):1639–46. DOI: 10.1161/STROKEAHA.118.020913
18. Gutierrez JA, Mulder H, Jones WS, Rockhold FW, Baumgartner I, Berger JS et al. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA Network Open. 2018;1(7):e185239. DOI: 10.1001/jamanetworkopen.2018.5239
19. van Kuijk JP, Flu WJ, Welten GMJM, Hoeks SE, Chonchol M, Vidakovic R et al. Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease. European Heart Journal. 2010;31(8):992–9. DOI: 10.1093/eurheartj/ehp553
20. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, FunckBrentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425
21. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2018;39(3):213–60. DOI: 10.1093/eurheartj/ehx419
22. Hiatt WR, Fowkes FGR, Heizer G, Berger JS, Baumgartner I, Held P et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. New England Journal of Medicine. 2017;376(1):32–40. DOI: 10.1056/NEJMoa1611688
23. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England Journal of Medicine. 2006;354(16):1706–17. DOI: 10.1056/NEJMoa060989
24. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology. 2007;49(19):1982–8. DOI: 10.1016/j.jacc.2007.03.025
25. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. New England Journal of Medicine. 2014;371(23):2155–66. DOI: 10.1056/NEJMoa1409312
26. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine. 2015;372(19):1791–800. DOI: 10.1056/NEJMoa1500857
27. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM et al. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease. JACC: Cardiovascular Interventions. 2017;10(9):942–54. DOI: 10.1016/j.jcin.2017.02.013
28. Bonaca MP, Bhatt DL, Storey RF, Steg PhG, Cohen M, Kuder J et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology. 2016;67(23):2719–28. DOI: 10.1016/j.jacc.2016.03.524
29. Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal. 2016;37(14):1133–42. DOI: 10.1093/eurheartj/ehv531
30. Fender A, Rauch B, Geisler T, Schrör K. Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation? Thrombosis and Haemostasis. 2017;117(11):2013–25. DOI: 10.1160/TH17-03-0219
31. Borissoff JI, Joosen IA, Versteylen MO, Spronk HM, ten Cate H, Hofstra L. Accelerated In Vivo Thrombin Formation Independently Predicts the Presence and Severity of CT Angiographic Coronary Atherosclerosis. JACC: Cardiovascular Imaging. 2012;5(12):1201–10. DOI: 10.1016/j.jcmg.2012.01.023
32. Gurbel PA, Bliden KP, Navickas I, Cohen E, Tantry US. Post-coronary intervention recurrent ischemia in the presence of adequate platelet inhibition by dual antiplatelet therapy: what are we overlooking? Journal of Thrombosis and Haemostasis. 2007;5(11):2300–1. DOI: 10.1111/j.1538-7836.2007.02749.x
33. Anand SS. Oral Anticoagulant Therapy in Patients With Coronary Artery Disease: A Meta-analysis. JAMA. 1999;282(21):2058–67. DOI: 10.1001/jama.282.21.2058
34. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. Journal of the American College of Cardiology. 2003;41(4 Suppl S):62S-69S. DOI: 10.1016/s0735-1097(02)02776-6
35. Andreotti F, Testa L, Biondi-Zoccai GGL, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. European Heart Journal. 2006;27(5):519–26. DOI: 10.1093/eurheartj/ehi485
36. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P et al. Apixaban with antiplatelet therapy after acute coronary syndrome. The New England Journal of Medicine. 2011;365(8):699–708. DOI: 10.1056/NEJMoa1105819
37. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C et al. Rivaroxaban in patients with a recent acute coronary syndrome. The New England Journal of Medicine. 2012;366(1):9–19. DOI: 10.1056/NEJMoa1112277
38. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2020;ehaa575. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehaa575
39. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli- Ducci C, Bueno H et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393
40. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017;377(14):1319–30. DOI: 10.1056/NEJMoa1709118
41. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2018;391(10117):205–18. DOI: 10.1016/S0140-6736(17)32458-3
42. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2018;391(10117):219–29. DOI: 10.1016/S0140-6736(17)32409-1
43. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139(9):1134–45. DOI: 10.1161/CIRCULATIONAHA.118.035864
44. Барбараш О.Л., Карпов Ю.А., Кашталап В.В., Бощенко А.А., Руда М.Я., Акчурин Р.С. и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):201-50. DOI: 10.15829/1560-4071-2020-4076
45. Hirsch AT. Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care. JAMA. 2001;286(11):1317–24. DOI: 10.1001/jama.286.11.1317
46. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004;172(1):95–105. DOI: 10.1016/S0021-9150(03)00204-1
47. Jönelid B, Johnston N, Berglund L, Andrén B, Kragsterman B, Christersson C. Ankle brachial index most important to identify polyvascular disease in patients with non-ST elevation or ST-elevation myocardial infarction. European Journal of Internal Medicine. 2016;30:55–60. DOI: 10.1016/j.ejim.2015.12.016
48. Lee J-Y, Lee S-W, Lee WS, Han S, Park YK, Kwon CH et al. Prevalence and Clinical Implications of Newly Revealed, Asymptomatic Abnormal Ankle-Brachial Index in Patients With Significant Coronary Artery Disease. JACC: Cardiovascular Interventions. 2013;6(12):1303–13. DOI: 10.1016/j.jcin.2013.08.008
49. Saleh A, Makhamreh H, Qoussoos T, Alawwa I, Alsmady M, Salah ZA et al. Prevalence of previously unrecognized peripheral arterial disease in patients undergoing coronary angiography. Medicine. 2018;97(29):e11519. DOI: 10.1097/MD.0000000000011519
50. Agnelli G, Cimminiello C, Meneghetti G, Urbinati S, Polyvascular Atherothrombosis Observational Survey (PATHOS) Investigators. Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events. Journal of Thrombosis and Haemostasis. 2006;4(12):2599–606. DOI: 10.1111/j.1538-7836.2006.02225.x
51. Serena J, Segura T, Roquer J, García-Gil M, Castillo J. The ARTICO study: identification of patients at high risk of vascular recurrence after a first non-cardioembolic stroke. BMC Neurology. 2015;15(1):28. DOI: 10.1186/s12883-015-0278-4
52. Hong JB, Leonards CO, Endres M, Siegerink B, Liman TG. AnkleBrachial Index and Recurrent Stroke Risk: Meta-Analysis. Stroke. 2016;47(2):317–22. DOI: 10.1161/STROKEAHA.115.011321
53. Бокерия Л.А., Покровский А.В., Акчурин Р.С., Алекян Б.Г., Апханова Т.В., Аракелян В.С. и др. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей. Москва. 2019. Доступно на: http://www.angiolsurgery.org/library/recommendations/2019/recommendations_LLA_2019.pdf
54. Lin JC, Kabbani LS, Peterson EL, Masabni K, Morgan JA, Brooks S et al. Clinical utility of carotid duplex ultrasound prior to cardiac surgery. Journal of Vascular Surgery. 2016;63(3):710–4. DOI: 10.1016/j.jvs.2015.10.008
55. Steinvil A, Sadeh B, Arbel Y, Justo D, Belei A, Borenstein N et al. Prevalence and Predictors of Concomitant Carotid and Coronary Artery Atherosclerotic Disease. Journal of the American College of Cardiology. 2011;57(7):779–83. DOI: 10.1016/j.jacc.2010.09.047
Рецензия
При поддержке: Статья подготовлена при поддержке компании "БАЙЕР" PP-XAR-RU-0723-1.
Для цитирования:
Грачев В.Г., Веденская С.С., Смоленская О.Г. Особенности антитромботической терапии у пациентов с мультифокальным поражением артерий. Кардиология. 2021;61(3):87-95. https://doi.org/10.18087/cardio.2021.3.n1498
For citation:
Grachev V.G., Vedenskaya S.S., Smolenskaya O.G. Features of Antithrombotic Therapy in Patients with Multifocal Arterial Disease. Kardiologiia. 2021;61(3):87-95. (In Russ.) https://doi.org/10.18087/cardio.2021.3.n1498
Просмотров: 658
Послать статью по эл. почте 
Оставить комментарий 